Biodegradable and next-generation implant alloys: Junction Brief – November 2026
Acentric Research is produced with AI tools under human review. The authors are not financial professionals, and nothing here is investment advice or a recommendation to buy or sell any security. AI analysis can be wrong; check every claim against its cited source.
This Brief is an initial scan, not a full investigation. The method and scores behind it are in Biotechnology × Materials in the Landscape Report.
Overview
Conventional metal implants are not designed to be absorbed; ARPA-H, for example, says joint replacement typically uses a titanium-alloy total joint. [1] A new class of implant is made of metals the body can absorb, chiefly magnesium alloys. The idea is that the implant holds a fracture in place while the bone heals, then dissolves, so no removal surgery is needed. This is a materials problem first: the alloy must be strong enough early on, then corrode away at a safe pace.
What stands out is that one product has reached an FDA decision. In March 2023 FDA granted a De Novo classification, a route for a new type of device with no earlier equivalent, to the RemeOs screw from Bioretec, and classified absorbable metal bone fasteners as a device type. [2] The screw is described by its maker as made of magnesium, calcium and zinc. [3] The sources opened show one authorized product, not a broad field. The dated sources opened are from 2023, and the company pages were read in November 2026; later developments were not searched.
Current state
What the material does. Bioretec's RemeOs screw is described by the company as made of magnesium, calcium and zinc, designed to dissolve over time without removal surgery. [3] Bioretec states on its home page that its implants degrade in the body in approximately two years. [4] These are company statements. The company also sells a second product line, Activa, based on a self-reinforced polymer (PLGA) with, it says, a long history in medical applications. [4] Its RemeOs page lists four screw types (LAG Solid, COM, LAG and FT) and marks some content as for markets outside the United States; the FDA order read covers only the LAG Solid. The page also says RemeOs is "ideal for adult and pediatric patients" (company claim), while the FDA indication is for skeletally mature adults. [3][2]
What FDA authorized. FDA received the De Novo request on 4 May 2022 and issued its order on 29 March 2023, about eleven months later. [2] The order covers the RemeOs Screw LAG Solid for fixation of bone fractures and of bone cuts made to correct deformities, in skeletally mature adults. The listed indication is fixation of the medial malleolus, the bony bump on the inner ankle. [2] FDA placed the device in Class II under the name "absorbable metallic bone fixation fastener" and said the order classifies substantially equivalent devices of this generic type into Class II. [2] Class II means FDA set special controls. These require clinical data showing the screw performs as intended, with the absorption profile characterized to completion, and testing of mechanical strength both at the start and as the device degrades. [2] The order lists the risks the controls address: early absorption, device breakage, galvanic corrosion, device aging, adverse tissue reaction, infection, and difficulty in revision surgery. [2]
Beyond magnesium. The scope of this Junction also includes next-generation alloys of other metals, such as titanium. ARPA-H notes that joint replacement for severe osteoarthritis typically uses a titanium-alloy total joint, and that about 2.5 million joint replacements are performed each year in the United States. [1] The sources opened describe no new titanium alloy product, so they say nothing on that part of the scope; other makers of absorbable or next-generation alloys were not searched for.
How far it has come. One magnesium-alloy screw has FDA marketing authorization (De Novo) for one ankle indication. A banner on Bioretec's home page, read on the access date, reads "Bioretec Receives CMS Pass-Through Payment for the US Market"; the page does not explain it and the linked release was not read. [4] This Brief did not search for sales figures or published clinical results.
Opportunities
Bioretec says its absorbable implants remove the need for a removal operation and reduce the long-term risks of permanent metal, naming stress shielding and osteolysis (company claims). [3] FDA's order set special controls for the device type. [2] The evidence that would show whether the benefit is real is clinical data comparing absorbable screws with standard ones, which this Brief did not search for.
Challenges
- Physics and engineering. The alloy must keep strength during healing and then be absorbed without harmful by-products. FDA lists premature absorption, absorption by-products and galvanic corrosion among the risks. [2]
- Regulation. The authorized indication is narrow: one screw, one bone, adult patients with mature skeletons. [2]
- Capital and scale-up. This Brief did not search for funding events or production costs for absorbable metal implants. [4]
Data sources
- FDA device databases, for De Novo, 510(k) and PMA records of this device type; the order read here came from them. [5]
- ClinicalTrials.gov, for studies of absorbable implants. [6]
- Company pages and investor releases, as company claims. [3]
- Europe PMC, for studies of degradation and clinical outcomes (not searched for this Brief). [7]
- No registry of sales or removal-surgery rates for these implants was identified.
Changelog
- 2026-11-18: First published.
Sources
- ARPA-H, "ARPA-H launches program to help joints heal themselves" (NITRO program launch), 2023-05-18 (agency statement). arpa-h.gov (accessed 2026-11-18)
- U.S. Food and Drug Administration, De Novo classification order DEN220030 (RemeOs Screw LAG Solid, Bioretec Ltd.), 2023-03-29. accessdata.fda.gov (accessed 2026-11-18)
- Bioretec, "RemeOs" product page (company statements). bioretec.com (accessed 2026-11-18)
- Bioretec, company home page (company statements). bioretec.com (accessed 2026-11-18)
- FDA De Novo database (the 510(k) and PMA databases are on the same site). accessdata.fda.gov (listed as a data source, not searched for this Brief; the two De Novo documents cited were opened as PDFs)
- ClinicalTrials.gov, study search. clinicaltrials.gov (listed as a data source; opened through its API only for two sponsor queries, 2026-11-18; not searched for this Junction)
- Europe PMC REST API. ebi.ac.uk (listed as a data source; two review abstracts were read through its API for other claims, 2026-11-18; not searched for this Junction)